Experts agree that vaccines are sorely needed to end the COVID-19 pandemic, and we are going to need hundreds of millions of doses. Johnson & Johnson together with multiple partners including Beth Israel Deaconess Medical Center (BIDMC) and BARDA* are working to develop a vaccine based on adenovirus vector technology and have committed to supply one billion doses.
But we cannot afford to bet on one horse. Fortunately, there are many vaccine candidates in development. To save lives, it is essential that innovators work together and share their knowledge and experience.
Join Dan Barouch from BIDMC and Hanneke Schuitemaker from the Janssen Pharmaceutical Companies of Johnson & Johnson for a discussion on what could be key success factors for the development of safe and effective vaccines, and for producing them in the immense quantities that are needed.
*The Janssen COVID-19 Vaccine project has been funded in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Agreement Number HHSO100201700018Cs.
Dan H. Barouch, MD, PhD
Professor of Medicine at Harvard Medical School and Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center (BIDMC)
Hanneke Schuitemaker, PhD
Vice President, Global Head Viral Vaccine Discovery and Translational Medicine at Janssen Vaccines & Prevention B.V
Hanneke is responsible for the portfolio of viral vaccine programs at Janssen. Most advanced programs in that portfolio are prophylactic and/or therapeutic vaccine candidates for COVID-19, HIV, RSV, Multivalent filo, Ebola, sIPV, Zika and HPV. In addition to her role at Janssen, Hanneke is also a Professor in Virology at the Amsterdam University Medical Center since 2004. Hanneke worked in academia for 20+ years on the pathogenesis of HIV infection and co-authored close to 300 peer reviewed scientific publications